Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038272 · ClinicalTrials.gov registry record · Phase 2
A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection
A Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 17
- Study locations
NCT00038272: Completed Phase 2 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00038272 is a Phase 2 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 56 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038272, a Phase 2 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, efficacy, and side effects of beta-D-2,6-diaminopurine dioxolane (DAPD) compared to DAPD plus mycophenolate mofetil (MMF) when these drugs are added to the anti-HIV treatment regimens of people infected with HIV. Some studies have shown that DAPD and MMF can help fight HIV. However, neither DAPD nor MMF has been approved by the Food and Drug Administration for treating HIV infection. This study will help doctors decide if DAPD and MMF are good drugs for treating HIV.
Conditions Studied
Interventions
- DRUG Mycophenolate mofetil
- DRUG Amdoxovir
Study Locations (17)
California
- UCLA CARE Center CRS - Los Angeles
- Stanford CRS - Palo Alto
- UC Davis Medical Center - Sacramento
- Univ. of California Davis Med. Ctr., ACTU - Sacramento
Pennsylvania
- Hosp. of the Univ. of Pennsylvania CRS - Philadelphia
- Univ. of Pennsylvania Health System, Presbyterian Med. Ctr. - Philadelphia
- Pitt CRS - Pittsburgh
New York
- Beth Israel Med. Ctr., ACTU - New York
- NY Univ. HIV/AIDS CRS - New York
Colorado
- University of Colorado Hospital CRS - Aurora
Florida
- Univ. of Miami AIDS CRS - Miami
Hawaii
- Univ. of Hawaii at Manoa, Leahi Hosp. - Honolulu
Maryland
- Johns Hopkins Adult AIDS CRS - Baltimore
Minnesota
- University of Minnesota, ACTU - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00038272 record still lists
NCT00038272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Mycophenolate mofetil is the first listed.
NCT00038272 lists 17 locations in 11 states (California, Pennsylvania, New York).
Frequently Asked Questions
What is clinical trial NCT00038272 about?
NCT00038272 is a clinical study titled "A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection". The purpose of this study is to evaluate the safety, efficacy, and side effects of beta-D-2,6-diaminopurine dioxolane (DAPD) compared to DAPD plus mycophenolate mofetil (MMF) when these drugs are added to the anti-HIV treatment regimens of people infected with HIV. Some studies have shown that DAPD...
What is the current status of trial NCT00038272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. Estimated completion is 2006-04.
What conditions does trial NCT00038272 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00038272?
The interventions under investigation include: Mycophenolate mofetil (DRUG), Amdoxovir (DRUG).
Who is sponsoring clinical trial NCT00038272?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00038272 being conducted?
This trial has 17 study locations across California, Colorado, Florida, Hawaii, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00038272's enrollment target sits among peer trials
56 341st of 542 higher than 200 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management